Industry News
Pharmaceutical Industry News
BeOne Medicines has extended its…
BeOne Medicines has extended its relationship with Blood Cancer United, committing $5 million over three years to support the nonprofit’s efforts to increase access to information and services.
Held just after the prestigious…
Held just after the prestigious Cannes Film Festival in southern France, the Cannes Lions Festival of Creativity has for years aimed to shine a spotlight on the world’s most creative brands and honor the best
Biogen is running a campaign aimed…
Biogen is running a campaign aimed at spreading awareness of the next-gen version of its spinal muscular atrophy therapy Spinraza.
Bayer has scored a key victory in…
Bayer has scored a key victory in its defense against Roundup lawsuits, as the U.S. Supreme Court has overturned a $1.25 million verdict from a jury in Missouri, which sided with a man who claimed
In a recent interview with Fierce,…
In a recent interview with Fierce, Fosun Pharma co-president, Xinli Wang, M.D., Ph.D., detailed how the company leveraged two recent deals to quickly build up its portfolio in Alzheimer’s disease as part of a multi-step
The FDA has accused Pinnacle…
The FDA has accused Pinnacle Biologics of creating videos that make it hard for healthcare professionals to “adequately process and comprehend the full indications” for a cancer drug.
With Merck KGaA’s former…
With Merck KGaA’s former electronics business lead Kai Beckmann now at the helm of the entire conglomerate, the new CEO is making his mark with a major outlay to support the company’s life sciences arm.
Jubilant HollisterStier, a CDMO…
Jubilant HollisterStier, a CDMO unit of India’s Jubilant Pharmova, earned an FDA warning letter after inspectors found its Montreal production plant lacked appropriate quality control systems.
Ionis has gained an FDA expansion…
Ionis has gained an FDA expansion for Tryngolza to become the first treatment specifically approved for severe hypertriglyceridemia. The nod will significantly increase the revenue-generating potential of the antisense oligonucleotide drug.
AstraZeneca has partnered with…
AstraZeneca has partnered with YMCA of the USA to increase awareness of cancer screening and early detection.
Living with a physical disability…
Living with a physical disability shouldn’t discount you from adventure. That’s the theme behind Novartis’ new “SMAshing My Limits And Going Places” campaign.
Shortage of Chemotherapy Drugs Brings Rationing Fears for Cancer Patients
Doctors are contending with low supplies and unfilled orders of generic chemotherapy infusions that are central to the treatment of a long list of cancers.
It’s been seven years since…
It’s been seven years since Pfizer scored an expansion for its blockbuster Ibrance. But it finally happened Wednesday with a nod as a maintenance therapy in HR+/HER2+ breast cancer.
Eli Lilly will focus on the…
Eli Lilly will focus on the telehealth market when it launches its oral obesity treatment Foundayo in Europe, Patrik Jonsson, the company's International chief, told Reuters. He added that the company's plan to sell Foundayo
The deal allows Stada to bolster…
The deal allows Stada to bolster its consumer health presence in European pharmacies while Orifarm sharpens its focus on pharmaceuticals.
In the wake of a recent safety…
In the wake of a recent safety scare in a confirmatory trial of its antibody-drug conjugate Zynlonta, ADC Therapeutics is tightening its belt in an effort to get the most out of its cancer med.
Julianne Hough is the new face of…
Julianne Hough is the new face of Revance’s Botox rival Daxxify. The company has enlisted the dancer, actress and host for an awareness and consumer education campaign designed to encourage people to try its wrinkle-busting
After a four-month investigation,…
After a four-month investigation, Nature Medicine has decided to pull a viral study that linked early-day PD-1/chemo treatment to a massive survival benefit versus late-day infusion in non-small cell lung cancer.
Incyte has dropped its lawsuit in…
Incyte has dropped its lawsuit in exchange for the CMS agreeing not to classify its JAK inhibitor cream Opzelura as a line extension of Jakafi.
AdvanCell, a clinical-stage…
AdvanCell, a clinical-stage radiopharmaceutical outfit, inked a lease near Boston to produce its prostate cancer candidate and set roots down for its U.S. headquarters.